Birchview Capital as of June 30, 2022
Portfolio Holdings for Birchview Capital
Birchview Capital holds 64 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 40.8 | $56M | 728k | 77.00 | |
| Aziyo Biologics (ELUT) | 7.3 | $10M | 1.4M | 7.07 | |
| Neurocrine Biosciences (NBIX) | 6.0 | $8.3M | 85k | 97.48 | |
| Quidel Corporation | 4.3 | $6.0M | 61k | 97.18 | |
| Foghorn Therapeutics (FHTX) | 2.8 | $3.9M | 285k | 13.60 | |
| Encana Corporation (OVV) | 2.7 | $3.7M | 84k | 44.19 | |
| United Therapeutics Corporation (UTHR) | 2.6 | $3.5M | 15k | 235.67 | |
| ACADIA Pharmaceuticals (ACAD) | 2.6 | $3.5M | 249k | 14.09 | |
| Biodesix (BDSX) | 2.1 | $2.9M | 1.8M | 1.62 | |
| Prothena Corp SHS (PRTA) | 2.0 | $2.8M | 103k | 27.15 | |
| Continental Resources | 1.8 | $2.5M | 39k | 65.36 | |
| Albireo Pharma | 1.6 | $2.2M | 113k | 19.86 | |
| Accelr8 Technology | 1.6 | $2.2M | 2.3M | 0.99 | |
| Biohaven Pharmaceutical Holding | 1.6 | $2.2M | 15k | 145.73 | |
| Phreesia (PHR) | 1.5 | $2.1M | 83k | 25.01 | |
| Masimo Corporation (MASI) | 1.5 | $2.0M | 15k | 130.69 | |
| Alkermes SHS (ALKS) | 1.1 | $1.5M | 50k | 29.80 | |
| Gossamer Bio (GOSS) | 1.0 | $1.3M | 159k | 8.37 | |
| Harrow Health (HROW) | 1.0 | $1.3M | 180k | 7.28 | |
| Karyopharm Therapeutics (KPTI) | 0.9 | $1.2M | 269k | 4.51 | |
| Corcept Therapeutics Incorporated (CORT) | 0.9 | $1.2M | 50k | 23.78 | |
| Cytokinetics (CYTK) | 0.7 | $982k | 25k | 39.28 | |
| Aveo Pharmaceuticals | 0.7 | $918k | 140k | 6.56 | |
| Pioneer Natural Resources (PXD) | 0.6 | $848k | 3.8k | 223.16 | |
| Equitrans Midstream Corp (ETRN) | 0.6 | $846k | 133k | 6.36 | |
| Inhibrx (INBX) | 0.6 | $800k | 70k | 11.36 | |
| 2seventy Bio (TSVT) | 0.6 | $790k | 60k | 13.20 | |
| Docgo (DCGO) | 0.6 | $785k | 110k | 7.14 | |
| Inari Medical Ord (NARI) | 0.5 | $680k | 10k | 68.00 | |
| Soleno Therapeutics | 0.5 | $680k | 3.7M | 0.18 | |
| ImmunoGen | 0.5 | $675k | 150k | 4.50 | |
| Arvinas Ord (ARVN) | 0.5 | $631k | 15k | 42.07 | |
| Contrafect | 0.4 | $614k | 200k | 3.07 | |
| Turning Point Therapeutics I | 0.4 | $602k | 8.0k | 75.25 | |
| Cullinan Oncology (CGEM) | 0.4 | $578k | 45k | 12.81 | |
| Apellis Pharmaceuticals (APLS) | 0.4 | $543k | 12k | 45.25 | |
| Chemocentryx | 0.4 | $496k | 20k | 24.80 | |
| Nektar Therapeutics (NKTR) | 0.4 | $486k | 128k | 3.80 | |
| Irhythm Technologies (IRTC) | 0.3 | $432k | 4.0k | 108.00 | |
| Amicus Therapeutics (FOLD) | 0.3 | $408k | 38k | 10.74 | |
| Bluebird Bio (BLUE) | 0.3 | $406k | 98k | 4.14 | |
| Ventyx Biosciences (VTYX) | 0.3 | $404k | 33k | 12.24 | |
| Kalvista Pharmaceuticals (KALV) | 0.3 | $394k | 40k | 9.85 | |
| Silk Road Medical Inc Common (SILK) | 0.3 | $364k | 10k | 36.40 | |
| Xencor (XNCR) | 0.2 | $337k | 12k | 27.40 | |
| Xenon Pharmaceuticals (XENE) | 0.2 | $304k | 10k | 30.40 | |
| Protagonist Therapeutics (PTGX) | 0.2 | $301k | 38k | 7.92 | |
| Kiniksa Pharmaceuticals (KNSA) | 0.2 | $291k | 30k | 9.70 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.2 | $225k | 8.0k | 28.12 | |
| BioCryst Pharmaceuticals (BCRX) | 0.2 | $212k | 20k | 10.60 | |
| G1 Therapeutics (GTHX) | 0.1 | $198k | 40k | 4.95 | |
| Stoke Therapeutics (STOK) | 0.1 | $198k | 15k | 13.20 | |
| Iveric Bio | 0.1 | $144k | 15k | 9.60 | |
| Inflarx Nv (IFRX) | 0.1 | $102k | 70k | 1.46 | |
| Concert Pharmaceuticals I equity | 0.1 | $84k | 20k | 4.20 | |
| Angion Biomedica Corp | 0.0 | $62k | 54k | 1.14 | |
| Laird Superfood (LSF) | 0.0 | $53k | 28k | 1.89 | |
| Aspira Womens Health | 0.0 | $49k | 83k | 0.59 | |
| Yield10 Bioscience | 0.0 | $42k | 19k | 2.24 | |
| Sientra | 0.0 | $34k | 40k | 0.85 | |
| Biogen Idec (BIIB) | 0.0 | $0 | 0 | 0.00 | |
| Vanda Pharmaceuticals (VNDA) | 0.0 | $0 | 0 | 0.00 | |
| Amarin Corp Spons Adr New (AMRN) | 0.0 | $0 | 0 | 0.00 | |
| Akebia Therapeutics (AKBA) | 0.0 | $0 | 0 | 0.00 |
